New and Updated Data from Studies of Opdivo and Yervoy Being Presented at ESMO Congress

New and Updated Data from Studies of Opdivo and Yervoy Being Presented at ESMO Congress

Bristol-Myers Squibb is presenting new data from numerous studies of its cancer therapies Opdivo (nivolumab) and Yervoy (ipilimumab) at the European Society for Medical Oncology (ESMO) 2016 Congress, with a particular focus on combination therapies for difficult-to-treat cancers.

The ESMO Congress is being held in Copenhagen on Oct. 7–11, attended by oncology clinicians and researchers from around the globe.

“We remain focused on expanding the use of the Opdivo and Yervoy combination to more tumors, and bringing forward novel agents and combination regimens in earlier lines of therapy, to help even more patients with cancer,” Fouad Namouni, MD, head of development, Oncology, Bristol-Myers Squibb, said in a news release.

In total, the company will be making 26 presentations, with most featuring studies of Opdivo and Yervoy. Below is a selection of research work that will be presented:


  • Opdivo was the focus of the CheckMate 275 trial (NCT02387996) in patients with metastatic urothelial cancer, and researchers will present the first efficacy and safety data from the trial.
  • Patient-reported outcomes in people with metastatic squamous cell carcinoma of the head and neck, from the Phase 3 CheckMate 141 (NCT02105636) trial comparing Opdivo with three other cancer drugs, will be reported.
  • Data collected from the CheckMate 026 (NCT02041533) Phase 3 trial, comparing Opdivo to platinum-based doublet chemotherapy as first-line treatment for recurrent or metastatic non-small cell lung cancer that is positive for PD-L1.


  • The first survival and safety data from the CA184-169 study (NCT01515189), comparing two doses of Yervoy — 3 mg/kg and 10 mg/kg — in patients with metastatic melanoma, will be reported.
  • An initial report of survival from the CA184-029 (NCT00636168) Phase 3 trial comparing Yervoy with placebo after complete resection of stage 3 melanoma will be presented.


  • In the Phase 2 CheckMate 064 trial (NCT01783938), researchers report identifying factors which associate with survival, as well as response to Opdivo and Yervoy combination treatment, in melanoma patients.
  • Researchers will present an interim analysis of the Phase 1/2 CheckMate 040 study (NCT01658878), evaluating the safety and offering a preliminary report of efficacy of Opdivo in patients with advanced hepatocellular carcinoma. One patient group in this trial is receiving a combination of Opdivo and Yervoy. This study is currently recruiting participants, and more information is available on its clinical webpage or by clicking on the study’s identification number, above.

A full list of presentations can be found here.

In addition, Bristol-Myers Squibb will host an investor teleconference during the ESMO conference, where data presented will be reviewed. Both investors and the general public are invited to listen to a live webcast of the call, which can be accessed by dialing toll-free (877) 258-2708, or internationally (647) 252-4456, and using the confirmation code: 74677318.